Pharma Industrial India Magazine - July - August 2024

LMI and PharmaLogic to Supply Neuraceq in Denver Life Molecular Imaging (LMI) has inked strategic partnership and licensing agreement with PharmaLogic to provide and distribute Neuraceq from Pharma- Logic’s radiopharmaceutical manufac- turing site located near Denver, CO. Neuraceq is an FDA-approved imaging agent for the detection of beta-amyloid plaques in the brain of adult patients with cognitive impairment who are be- ing evaluated for Alzheimer’s disease and other causes of cognitive decline. Neuraceq is used in clinical routine and is also a powerful imaging biomarker for the appropriate characterization of patients assessed for treatment eligi- bility with newly approved anti-amyloid drugs, or for enrollment in clinical trials to further support drug development in neurodegenerative diseases. “By partnering with PharmaLogic and offering Neuraceq in Denver, Life Mo- lecular Imaging is excited to expand access of Neuraceq for the detection of beta-amyloid plaques in the brain. We believe this additional access benefits physicians and patients, as well as our pharma partners for routine clinical and research use. We are excited to collab- orate with Pharmalogic today and look forward to more opportunities in the future. “ said Ludger Dinkelborg, PhD, Managing Director at LMI. LSPedia has signed a strategic partner- ship with Pharma Logistics, the industry leader in pharmaceutical reverse distri- bution. This collaboration aims to transform the pharmaceutical supply chain by offer- ing turnkey compliance, unprecedent- ed data visibility, and robust supply chain efficiency. Compliance is at the core of Pharma Logistics’ business model, aligning with the broader industry goal of enhancing healthcare affordability and ensuring the compliant handling of pharmaceu- ticals. With rigorous processes, Pharma Logistics ensures that pharmaceutical products are handled efficiently and safely throughout their end-of-life cycle providing customers with unmatched visibility, simplified returns, and action - able insights. This partnership enhances value for the combined customer base of both com- panies. The integrated solution enables health systems, pharmacies, and other stakeholders to access a comprehen- sive 360-degree view of the pharma- ceutical supply chain, from manufac- turing to end-of-life processing. For the first time, pharmaceutical companies can rely on a single, trusted source of information to make informed business decisions faster and with greater con- fidence. “We are delighted to offer LSPedia’s OneScan solution to our pharmacy customers. Our customers have con- sistently highlighted the challenge of managing complex DSCSA compli- ance requirements and ensuring accu- rate product traceability. By integrating OneScan, we are addressing these crit- ical pain points and making advanced compliance technology more acces- sible. This partnership enables us to provide a more seamless, efficient, and reliable solution, empowering our cus- tomers to stay ahead in the ever-evolv- ing regulatory landscape,” said David A. Hargraves, CEO of Pharma Logis- tics. LSPedia’s OneScan solution is the lead- ing platform for achieving complete compliance with the FDA’s DSCSA reg- ulations. It delivers to customers a trans- parent view of the pharmaceutical sup- ply chain with real-time product tracing data at the serial, lot, order, and NDC level. When seamlessly integrated with the hospital and pharmacy systems, the innovative platform significantly reduc - es redundant product scanning across various systems, streamlines complex recall management, and mitigates the risk of drug shortages. NEWS PHARMA INDUSTRIALINDIA · JUL-AUG 24 24 LSPedia, Pharma Logistics to Advance Pharmaceutical Reverse Logistics